Connecticut et al v. Sandoz, Inc. et al
Case Number:
3:20-cv-00802
Court:
Nature of Suit:
Judge:
Firms
- Armstrong Teasdale
- Arnold & Porter
- Bailey Duquette
- Baker Botts
- Clifford Chance
- Cole Schotz
- Competition Law Partners
- Day Pitney
- Debevoise & Plimpton
- Dechert LLP
- DLA Piper
- Faegre Drinker
- Gage Spencer & Fleming
- Harris Beach Murtha Cullina PLLC
- Hinckley Allen
- Hogan Lovells
- Kelley Drye
- Linklaters LLP
- Mintz Levin
- Morgan Lewis
- Norton Rose
- O'Toole & O'Toole
- Petrillo Klein
- Proskauer Rose
- Ropes & Gray
- Saul Ewing
- Saxton & Stump
- Shapiro Arato
- Skadden Arps
- Troutman
- Wiggin & Dana
- Wilson Sonsini
Companies
- Allergan PLC
- Amneal Pharmaceuticals Inc.
- Aurobindo Pharma Ltd.
- Bausch Health Cos. Inc.
- Fougera Pharmaceuticals Inc.
- Glenmark Pharmaceuticals Ltd.
- G&W Laboratories Inc.
- Lannett Company, Inc
- Lupin Ltd.
- Mallinckrodt PLC
- Optum Inc.
- OptumRx Inc.
- Perrigo Co. PLC
- Pfizer Inc.
- Sandoz International GmbH
- Teva Pharmaceutical Industries Ltd.
- Viatris Inc.
- Wockhardt USA LLC
Government Agencies
- Commonwealth of Kentucky
- Commonwealth of Massachusetts
- State of Indiana
- State of Maryland
- State of Michigan
- State of Nevada
- State of Tennessee
- U.S. District Court for the District of Columbia
Sectors & Industries:
-
July 09, 2025
Sandoz, Buyers Defend $275M Deal Amid State Objections
Counsel for consumers, insurers and others urged a Pennsylvania federal court on Tuesday to approve Sandoz and its subsidiaries' $275 million deal settling claims it conspired with other companies to fix some generic drug prices, with Sandoz separately calling states' objections "a paternalistic desire to control private class action settlements."
-
July 03, 2025
States Still Oppose Florida's Generic Drug Deal With Sandoz
States accusing generic-drug makers of fixing prices are continuing to object to a $10 million settlement struck between Florida and Sandoz, arguing that it limits their ability to negotiate deals while letting the Sunshine State benefit without participating in the litigation.
-
June 18, 2025
Ex-Drug Exec Must Testify, But Keeps 5th Amendment Rights
Sandoz, Teva, Actavis and Taro can again subpoena the deposition testimony of a former Actavis and Teva executive, but a Pennsylvania federal judge is still allowing the witness to invoke his Fifth Amendment rights against self-incrimination, even though the Justice Department dropped the criminal charges against him.
-
June 12, 2025
Florida, Sandoz Say They've Fixed Generic Drug Price-Fix Deal
The Florida Attorney General's Office and Sandoz Inc. have told a Connecticut federal court they've fixed the problems the court identified with a generic drug price-fixing settlement after other states with claims in the case objected to a clause in the deal.
-
June 09, 2025
5th Amendment Can't Shield Ex-Exec, Drugmakers Argue
Generic-drug makers urged a Pennsylvania court to compel a former executive to sit for a deposition in ongoing price-fixing litigation despite his invocation of the Fifth Amendment, arguing his testimony is crucial to their defense.
-
May 12, 2025
Missouri Hit With Sanctions In Generics Price-Fixing Fight
A Connecticut federal judge Monday agreed to sanction and potentially dismiss for good the state of Missouri from antitrust litigation by state enforcers accusing generic-drug makers of conspiring to raise drug prices, finding Missouri violated a court order by ignoring the drugmakers' repeated discovery requests.
-
May 01, 2025
Payment Math Dooms Sandoz Price-Fixing Deal With Florida
A Connecticut federal judge on Thursday refused to put a bow on the deal the state of Florida struck with Sandoz AG and related defendants in three generic drug price-fixing lawsuits, ruling from the bench in Hartford that the settlement agreement "as written" would lead to exorbitant supplemental payments in the event that other states also reach deals to release their claims.
-
April 03, 2025
$10M Heritage Pharma Price-Fixing Deal Gets Final OK
A Connecticut federal judge granted final approval to a $10 million deal between Heritage Pharmaceuticals Inc., its parent company Emcure Pharmaceuticals Ltd. and Emcure's founder Satish Mehta to resolve claims from a coalition of states accusing them of conspiring with other companies to inflate generic drug prices.
-
March 26, 2025
AGs Seek 1st OK For $39M Apotex Deal In Price-Fixing Case
A coalition of 50 state attorneys general on Wednesday asked a Connecticut federal judge to accept a $39.1 million deal settling claims that pharmaceutical company Apotex Corp. schemed with others to fix generic-drug prices, with 70% earmarked for a restitution fund and 30% for consumer notices and attorney fees.
-
March 03, 2025
Sandoz Settles Florida's Generic Drug Price-Fixing Claims
Sandoz AG reached a settlement with Florida that ends federal antitrust claims the Sunshine State lodged against the drugmaker within wider litigation claiming numerous pharmaceutical companies and individuals participated in a conspiracy to fix generic drug prices, according to a Friday court filing.